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CARDIOVASCULAR DISORDERS—
Clinical Outcomes Studies
PCV1
THE ROLE OF LDL-LEVELS IN INITIATING STATIN
TREATMENT
van der Bij S1, Heintjes E1, Plat A1, Sturkenboom MC2,
Penning-van Beest FJ1, Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2Erasmus University
Medical Center, Rotterdam,The Netherlands
OBJECTIVES: To assess the proportion of patients initiated on
statin treatment among patients of various cardiovascular risk
groups and the probability of statin treatment given certain LDL-
levels in daily practice. METHODS: From the PHARMO-
database, we selected patients who had an LDL-measurement in
2006 and no statin use in the year before. Per category of LDL-
levels, i.e. 2.5, 2.6–4.0, 4.1–5.0 and >5.0 mmol/l, we deter-
mined the proportion of patients treated within 6 months after
the measurement among those with cardiovascular disease
(CVD, group I), with diabetes type 2 and no CVD (DM2, group
II), and without CVD or DM2 (group III). The association
between LDL-levels and statin treatment was determined using
logistic regression adjusting for age, gender, CVD and DM2.
RESULTS: Group I included 14,267 patients, group II 9,224
patients, and group III 54,102 patients. Overall, the proportions
of patients receiving statins within 6 months after LDL-
measurement were 19% for group I and II and 8% for group III.
These proportions ranged from 8%, 6% and 2% for patients
with baseline LDL-levels 2.5 mmol/l, to 49%, 43% and 32%
in patients with LDL-levels >5.0 mmol/l. Multivariate modelling
showed that compared to patients with LDL 2.5 mmol/l
(reference) the relative probability of statin treatment increased
with LDL-levels: RR 2.6 (2.4–2.9) for 2.6–4.0 mmol/l, RR 5.8
(5.3–6.3) for 4.1–5.0 mmol/l, and RR 11.9 (10.9–13.1) for
>5.0 mmol/l. Patients with CVD (RR 2.0 (1.9–2.1)) or DM2 (RR
2.5 (2.4–2.7)) were more likely to receive statin treatment. CON-
CLUSIONS: This study shows that, as expected, among statin-
naïve patients the probability of statin treatment following LDL
measurement increased with higher LDL-levels and pre-existing
morbidity. However, the potential to further improve health out-
comes exists because, even among patients with known CVD
or DM2, approximately 55% of patients with LDL levels
>5.0 mmol/l did not receive statin treatment.
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OBJECTIVES: It has been hypothesized that patients suffering
from cardiovascular diseases (CVD) and diabetes type 2 (DM2)
beneﬁt most from treatment with statins. In this study, we deter-
mined the proportion and characteristics of patients who, despite
recommendations in treatment guidelines, were not treated with
statins METHODS: Patients registered with a GP in the IPCI-
PHARMO GP database at January 1, 2007 that had a history of
CVD without DM2 (Group I) or DM2 without CVD (Group II)
were selected. The proportion of patients using statins between
July 2006 and June 2007 was determined among individual
cohorts of patients suffering either from CVD (Group I) or DM2
(Group II). Factors associated with non-treatment with statins
were identiﬁed and quantiﬁed using logistic regression modelling.
RESULTS: In our database we could identify and classify 19,623
CVD patients (Group I) and 5,007 DM2 patients (Group II). Of
these patients, statins were not used by 71% of Group I members
nor by 54% of Group II members. Multivariate modelling
showed that low-socioeconomic status and younger age were
signiﬁcantly (p < 0.05) associated with under-treatment with
statins, both among high risk patients suffering from either CVD
or DM2. CONCLUSIONS: From this study we can conclude
that a very large percentage of patients with established cardio-
vascular risk factors or diabetes where not treated with statins as
recommended in treatment guidelines. Detailed analyses showed
that younger patients and patients with a low-socio economic
status were more likely to not be receiving statins.
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OBJECTIVES: The use of simvastatin 40 mg is stated as the
preferred statin treatment in the 2006 Dutch guideline for car-
diovascular risk management. We studied whether this recom-
mendation showed equal or better goal attainment rates in
routine daily practice compared to patients treated with other
statins. METHODS: Using the PHARMO data network we iden-
tiﬁed all patients starting statin use in the period 1999 through
2006. Patients suffering from cardiovascular disease or diabetes
type 2 were classiﬁed as high risk. Treatment goals were deﬁned
according to the guidelines of the European Society of Cardiol-
ogy (2003). Goals for total cholesterol (TC) and low density
lipoprotein cholesterol (LDL-C) were <4.5 and <2.5 mmol/l for
high risk patients and <5.0 and <3.0 mmol/l for low risk patients.
Patients at goal at baseline were excluded. Goal attainment rates
at 12 months were compared between simvastatin 40 mg and
other statins and doses using logistic regression adjusting for age,
gender, year of statin use, CVD, DM2, baseline LDL-C and
adherence. RESULTS: We identiﬁed 7356 new statin users of
which 70% were categorised as being at high risk. Goal attain-
ment rates were similar in the low and in high risk patient
groups. Fifty-eight percent of patients treated with simvastatin
40 mg attained goal. Both atorvastatin 20 and 40 mg (RR 1.16
and 1.22) and rosuvastatin 10 and 20 mg (RR1.18 and 1.51)
yielded signiﬁcantly higher goal attainment rates compared to
patients treated with simvastatin 40 mg. CONCLUSIONS:
Results from this study strongly suggest that even after correction
of differences in dosing and baseline LDL-C levels, goal attain-
ment with statins in the ﬁrst year of treatment is signiﬁcantly
more frequent among patients using atorvastatin or rosuvastatin
than in patients using simvastatin 40 mg. Other studies suggest
that these differences translate into reduced cardiovascular risk.
This evidence from routine daily practice questions whether
recommending simvastatin 40 mg is most beneﬁcial to patients.
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COMPARISON OFTHE CLINICAL AND ECONOMIC
EFFECTIVENESS OF SIROLIMUS-ELUTINGVERSUS
BARE-METAL STENTS IN A SUBGROUP OF PATIENTS
WITH AND WITHOUT DIABETES
Brüggenjürgen B, McBride D, Roll S,Willich SN
Charité University Medical Center, Berlin, Germany
OBJECTIVES: To evaluate the effectiveness of sirolimus-eluting
stents (SES) to bare-metal stents (BMS) in a subgroup of patients
with and without diabetes. METHODS: In the prospective
GERSHWIN study in 35 hospitals in Germany, patients with
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